Literature DB >> 9001716

A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.

M Gerlach1, W Gsell, J Kornhuber, K Jellinger, V Krieger, F Pantucek, R Vock, P Riederer.   

Abstract

Functional models of the circuitry of the basal ganglia have recently been proposed to account for the vast spectrum of motor disorders associated with the loss of anatomical or neurochemical integrity within the basal ganglia. On the basis of these hypothetical models, hypokinetic disorders such as Parkinson's disease, are thought to be associated with excessive tonic and phasic inhibition of the output from the basal ganglia to the thalamus. In the present study we have attempted to determine the validity of the proposed model by measuring neurochemical markers of inhibitory and excitatory neurotransmission in post mortem human brain tissue. We have determined the concentrations of the excitatory neurotransmitters aspartate/glutamate and of the inhibitory neurotransmitter GABA in 18 relevant regions of the thalamocortical circuits of the basal ganglia of patients who had manifested Parkinsonian symptoms, and compared them with controls of individuals who had died without any history of neurological or psychiatric disorders and had no neuropathological abnormalities. Additionally, the receptor subtype for the excitatory amino acid N-methyl-D-aspartate (NMDA) was studied in the same brain tissue in which neurotransmitter concentrations had been analysed as neurochemical markers of post-synaptic excitatory neurotransmission. In patients who had manifested Parkinsonian symptoms, glutamate and aspartate levels were found to be unchanged in all examined brain regions. In contrast, the binding of [3H]MK-801, which identifies the NMDA receptor, was reduced in the head (-42%) and body (-38%) of the caudate nucleus. In parkinsonian patients, GABA levels were diminished by 36% in the centromedial thalamus, compared to control values. These results do not confirm the changes in neurotransmitter concentrations predicted according to the model, although we cannot rule out that the predicted changes might have been observed if the Parkinsonian group had been further subdivided into groups diagnosed on the basis of the patients' clinical picture (akinetic-rigid, tremor-dominant, equivalent type) and compared with the control group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9001716     DOI: 10.1016/s0006-8993(96)00915-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

Review 1.  The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states.

Authors:  Yoland Smith; Dinesh Raju; Bijli Nanda; Jean-Francois Pare; Adriana Galvan; Thomas Wichmann
Journal:  Brain Res Bull       Date:  2008-09-19       Impact factor: 4.077

Review 2.  Ion channels as drug targets in central nervous system disorders.

Authors:  A M Waszkielewicz; A Gunia; N Szkaradek; K Słoczyńska; S Krupińska; H Marona
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks.

Authors:  M Alkondon; E F Pereira; H M Eisenberg; E X Albuquerque
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

4.  Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling.

Authors:  Javorina Milosevic; Martina Maisel; Florian Wegner; Julia Leuchtenberger; Roland H Wenger; Manfred Gerlach; Alexander Storch; Johannes Schwarz
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

5.  Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease.

Authors:  Amélie C Lanoue; Alexandra Dumitriu; Richard H Myers; Jean-Jacques Soghomonian
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

6.  Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.

Authors:  A Raz; E Vaadia; H Bergman
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

7.  Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA.

Authors:  M S Nandhu; Jes Paul; Korah P Kuruvila; Pretty M Abraham; Sherin Antony; C S Paulose
Journal:  Mol Cell Biochem       Date:  2011-03-08       Impact factor: 3.396

8.  Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms.

Authors:  Christian Pifl; Stephen J Kish; Oleh Hornykiewicz
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 10.  Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.

Authors:  Susan Duty
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.